International Web-based consultation on priorities for translational breast cancer research

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Dowsett, Mitch ^a   Goldhirsch, Aron ^b   Hayes, Daniel F ^c   Senn, Hans Joerg ^d   Wood, William ^e   Viale, Giuseppe ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Tumor Center ZeTuP   (Switzerland)

^e EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RESEARCH; CONSENSUS DEVELOPMENT; CONSULTATION; DATA BASE; E-MAIL; EUROPE; GENE MUTATION; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; IMMUNOHISTOCHEMISTRY; NORTH AMERICA; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCIENTIST; SYMPOSIUM; TRANSLATIONAL RESEARCH; TRIPLE NEGATIVE BREAST CANCER; WEB BROWSER; BREAST TUMOR; CANADA; CARCINOMA IN SITU; FEMALE; INTERNATIONAL COOPERATION; INTERNET; JAPAN; MEDICAL RESEARCH; METABOLISM; PAGET NIPPLE DISEASE; STATISTICS; STEM CELL; TELECOMMUNICATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CANADA; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; INTERNET; JAPAN; STEM CELLS; TELECOMMUNICATIONS; UNITED STATES;

EID: 40349103608     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1798     Document Type: Article

References (7)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874 10.1073/pnas.191367098.
2. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009 10.1056/NEJMoa021967.
3. Top Ten: a global consensus. [ http://www.toptenresearch.org ]
4. Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD: Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003, 14: 1212-1214 10.1093/annonc/mdg327.
5. Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006, 7: 347-350.
6. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, et al: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006, 3: 540-551 10.1038/ncponc0591.
7. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006, 59: 729-735 10.1136/jcp.2005.033043.